Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination
By Robert Gorter, MD, PhD, et. al.
Robert Gorter, is emeritus professor of the University of California San Francisco (UCSF)
Since the early 1990’s, Robert Gorter of the Medical Center Cologne (MCC) has often warned that he noticed a clear increase of autoimmune diseases like bone marrow depression with life-long thrombocytopenia (<10.000 thrombocytes) among health care providers who were legally obliged to be vaccinated against hepatitis B if they had contact with patients. He wondered why he saw so many autoimmune diseases among the health care providers he had vaccinated both in San Francisco, California, and in Berlin and in the Ruhr region in Germany.
Recently, Ethan A. Huff made an extensive literature study and could document in a meta-analysis in Natural News and about the publications by Dominique Le Houezec that the sudden and sharp increase in the number of multiple sclerosis (MS) cases diagnosed in France appears to have its roots in a mass vaccination campaign for hepatitis B, that was launched by the World Health Organization (WHO), according to new epidemiological data published in the journal Immunologic Research.
In accordance with WHO recommendations, France implemented a campaign in 1992 promoting hepatitis B vaccines, for which twenty million French adults – or roughly one-third of the country -agreed to be vaccinated between the years of 1994 and 1997. By 1998, however, massive spikes in MS cases began to dominate headlines in the French media. The number of MS was very stable, about 2,500 new cases each year until 1993. The following years, and especially since 1996, a progressive increase in the number of new MS reported to the Health Insurance occurred. This figure increased to about 4,500 cases in 2003 and remains steady since.
Prior to 1993, when the hepatitis B vaccine campaign first began, there were about 2,500 new cases of MS in France annually. Immediately after the campaign was launched, and especially after 1996, that number nearly doubled to 4,500 new MS cases per year. The most obvious cause, according to many health experts, was the vaccine. Immediately following this revelation, vaccination rates plummeted in France and suspicions about how the hepatitis B vaccine might be triggering MS, began to emerge. One hypothesis suggested that a protein in the vaccine might be very similar to a protein naturally found in myelin, the protective coating around nerve fibers that is attacked by the immune system in MS sufferers.
Since that time, multiple research projects have aimed to better understand the correlation between hepatitis B vaccines and MS. One French study found that the actual number of MS cases linked to hepatitis B vaccines is 2.5 times higher than previously assumed, while another case-controlled epidemiological study observed a definitive increased risk of MS within three years following vaccination.
These studies and others were included in the latest review, which confirmed a “significant correlation” between hepatitis B vaccines and MS cases. A graph featured in the study shows a massive spike in MS cases in 1996, which directly matches the 2-3-year period following vaccination that previous studies had documented was when most MS cases would likely emerge due to the vaccine.
“The positive and statistically significant correlation between Hepatitis B vaccine exposure and reported MS incidence is consistently observed in different places, circumstances, and times”, wrote the authors. “The figures available in France thus show a definite statistical signal in favor of a causal link between the HB vaccine event and the apparition of MS with a maximum correlation in the two years following immunization.”
Based on the compelling findings of this study, its authors were bold enough to declare the hepatitis B vaccine campaign a “large scale experiment” on the French people, and one that very clearly had dire consequences. MS isn’t a disease to mess with, and those who suffer from it will be the first to tell you how excruciating it is to deal with on a daily basis.
With this in mind, it is absolutely vital to carefully consider the risks involved when getting your child vaccinated, or when getting vaccinated yourself. Should the hepatitis B vaccine happen to trigger an autoimmune response by which your immune system starts attacking your central nervous system, there’s no going back.
“As of March 2012, there was a total of 66,654 hepatitis B vaccine-related adverse events reported to the federal Vaccine Adverse Events Reporting System (VAERS), including reports of headache, irritability, extreme fatigue (CFS), brain inflammation with life-long decreased mental functioning, convulsions and epilepsy, rheumatoid arthritis, life-long thrombocytopenia, optic neuritis, multiple sclerosis, lupus, Guillain Barre Syndrome (GBS) and neuropathy”, explains the National Vaccine Information Center (NVIC) about the risks associated with this deadly vaccine.
Published in Immunol Res: DOI 10.1007/s12026-014-8574-4 (2014).
Robert Gorter, MD, PhD has been an expert in the treatment of chronic viral infections, including HIV, Hepatitis B and C. Already in the 1970’s, he was instrumental in prevention of the spread of Hepatitis B (at that time called the “Australia Antigen”) by setting up free and low threshold Needle Exchange Programs for intravenous drug users in Amsterdam and Rotterdam. He was often called the “Clean Doctor” because of his vegetarian life style without alcohol, tobacco, or other sins (except chocolate).
For years, Gorter was the Medical Director of the Department for AIDS Epidemiology and Biostatistics and in that function Gorter studied extensive the natural progression of HIV infection to full-blown AIDS, and the efficacy of prevention programs among high risk populations at the University of California San Francisco(UCSF). Also, he studied the prevalence and incidence rates of other retroviral infections (HLTV-1 and -2 and -4) among blood donors. In the mid 1980’s it became mandatory for health care workers in the USA and EU to be vaccinated with (recombinant) Hepatitis B vaccines. Also Gorter was vaccinated.
In his function as a Clinical Associate Professor at UCSF, he was obliged to vaccinate hundreds of collaborating health care professionals at San Francisco General Hospital (SFGH). It struck him that quite a few coworkers he had vaccinated called in sick a few days to weeks later and complained of fatigues and long-lasting loss of concentration. He even submitted a grant application at the National Institute of Health (NIH) in Washington DC to study the possible correlation between possible brain and nerve damage and Hepatitis B vaccination. But the application was rejected as “not high priority.”
Over the years, Robert Gorter observed quite a few health care providers in Germany who had developed autoimmune diseases a few months after a vaccination.
Sources for this article: